Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Policy / Regulatory

NMPA Adds 35 New Reference‑Listed Drugs to 95th Catalog, Updates 31 Existing Specs

Fineline Cube Sep 3, 2025

The National Medical Products Administration (NMPA) today announced the release of its 95th Reference‑Listed Drugs...

Company Drug

Hengrui Pharma Secures NMPA Approval for HRS‑7172 Targeting RAS‑Mutated Tumors

Fineline Cube Sep 3, 2025

China‑based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) today announced that its novel...

Company Drug

MSD Reports Positive Phase 3 CORALreef Lipids Results for Oral PCSK9 Inhibitor Enlicitide

Fineline Cube Sep 3, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) disclosed encouraging topline results from the...

Company Deals Drug

OMass Therapeutics Teams Up with Genentech on First‑in‑Class IBD Oral Small Molecule

Fineline Cube Sep 3, 2025

OMass Therapeutics, a biotechnology firm that discovers medicines targeting membrane proteins and intracellular complexes, has...

Company Deals

Arrowhead Partners with Novartis for ARO‑SNCA siRNA Therapy

Fineline Cube Sep 3, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today unveiled a worldwide licensing and collaboration agreement with Novartis...

Company Deals

Novatim Licenses KY‑0301 Nano‑Bispecific ADC to RADIANCE Biopharma

Fineline Cube Sep 2, 2025

Novatim Immune Therapeutics (Zhejiang) Co., Ltd. announced a landmark exclusive licensing collaboration with RADIANCE Biopharma....

Company Drug

Zai Lab’s TIVDAK Wins Hong Kong Approval for Recurrent Cervical Cancer

Fineline Cube Sep 2, 2025

China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has secured a pivotal regulatory milestone:...

Company Drug

Fosun Launches Futuoning, First‑In‑Class CDK4/6 Inhibitor for HR‑Positive Breast Cancer

Fineline Cube Sep 2, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced the nationwide launch of...

Company Drug

Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations

Fineline Cube Sep 2, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that the Biologics License...

Company Drug

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977

Fineline Cube Sep 2, 2025

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that the U.S. Food and Drug Administration...

Company Drug

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China

Fineline Cube Sep 2, 2025

Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced the commercial launch of Tapcom (tafluprost/timolol maleate) in...

Company Deals

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies

Fineline Cube Sep 2, 2025

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149) and Hayoo Biotech have...

Company Drug

Sino Biopharmaceutical’s Benmelstobart‑Anlotinib Combo Secures NMPA NDA for Advanced ASPS

Fineline Cube Sep 2, 2025

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Ltd...

Company Drug

Hansoh Pharma Secures Second FDA‑Approved Indication for Inebilizumab in IgG4‑Related Disease

Fineline Cube Sep 2, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its inebilizumab injection has received...

Others

Sanofi’s Wayrilz FDA Approval Brings New Oral BTK Inhibitor for ITP

Fineline Cube Sep 1, 2025

The U.S. Food and Drug Administration (FDA) has granted approval to Sanofi’s (NASDAQ: SNY) Wayrilz...

Company Deals

Eli Lilly & JD Health Form Digital Care Alliance for Obesity, Diabetes, and Alopecia

Fineline Cube Sep 1, 2025

Eli Lilly (NYSE: LLY) China has announced a strategic partnership with JD Health (HKG: 6618)...

Company Drug

Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone

Fineline Cube Sep 1, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its oral primary biliary cholangitis (PBC) treatment,...

Company Drug

Bioheng Therapeutics Receives FDA RPDD for Off‑The‑Shelf CAR‑T CTD402

Fineline Cube Sep 1, 2025

Bioheng Therapeutics (China) announced that the U.S. Food and Drug Administration (FDA) has granted Rare...

Company Deals

JCBio & MGI Launch Korea’s First DCS Lab to Accelerate Multi‑Omics Innovation

Fineline Cube Sep 1, 2025

South Korean biotechnology firm JCBio and global genomics leader MGI Tech Co., Ltd. today signed...

Company Deals Medical Device

IVD Medical Acquires 20 % of GoFintech in HK$3.14 B Deal

Fineline Cube Sep 1, 2025

IVD Medical Holding Limited (HKG: 1931) disclosed that it will purchase 1,848,496,429 shares of GoFintech...

Posts pagination

1 … 142 143 144 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.